It's likely that other analytes, like circulating tumor DNA, will meet up with this threshold in the next few years, said first author, Bert Gold, PhD, National Cancer Institute. Generally, the article supports the idea that this kind of diagnostic screening in and of itself allows for earlier diagnosis, faster and even more targeted treatment, decreased costs, and increased standard of living and even increased lifespan for the patient. The article also contains recommendations for future trials which will ultimately result in demonstrating the scientific utility of the referenced minimally invasive methods.We plan to build on this momentum in 2014 as we spend money on our key products, enhance our pipeline, and plan significant item launches that may drive growth in 2015 and beyond. Fourth-Quarter Outcomes Worldwide sales were $5.111 billion in the fourth quarter, down 1.8 %. On an operational basis, product sales reduced 1.1 %, excluding a 0.7 % unfavorable impact from forex rate fluctuations. Excluding product sales from our lipid franchise because of the lack of exclusivity, sales increased 7.9 % on an operational basis in the quarter. Fourth-quarter sales had been led by the continued power of HUMIRA. Global HUMIRA sales increased 13.4 %. U.S. HUMIRA sales grew 18.1 %. Fourth-one fourth modified gross margin ratio was 77.1 %, excluding intangible asset amortization and various other specified items.